Nanolek's delegation, led by CEO Vladimir Nesterenko, participated in the Second Russian-Chinese Pharmaceutical Forum held in Shanghai, China, as part of the CPHI China International Pharmaceutical Exhibition. The team also successfully engaged in numerous discussions with local companies.
The Forum featured a diverse lineup of speakers who addressed a wide range of topics related to collaboration between Russian and Chinese companies in areas such as research and development, clinical trials, registration, quality control, localization, and the import and export of pharmaceutical products.
During the general panel discussion at the Forum, Nanolek was represented by Arina Privalova, Director of Strategic Development. In a Nanolek's separate private meeting with Chinese companies, she emphasized the following:
"Although Russia has a much smaller population compared to China, the monetary value of our pharmaceutical market is only four times smaller than that of China, making it quite comparable to other major markets like India. This presents a valuable opportunity for Chinese companies looking to expand internationally. There is great interest from these companies in entering the Russian market, both in terms of new products launch and joint technology development and transfers. During the private meeting, we outlined the regulatory framework of the Russian market and discussed the most effective strategies for market entry with representatives of Chinese companies. The feedback was overwhelmingly positive and confirmed the strong interest of our Chinese colleagues in the Russian pharmaceutical sector."
In addition to participation from Russian and Chinese companies, the Forum also saw attendance from representatives of government regulatory agencies, including the Ministry of Health and the Ministry of Industry and Trade of the Russian Federation, as well as the Chinese Association of Pharmaceutical Manufacturers and the Chinese Chamber of Commerce for Import and Export of Medicines and Healthcare Products.
During the Forum, government priorities for pharmaceutical cooperation with China were made public. Ekaterina Prieszheva, Deputy Minister of Industry and Trade of the Russian Federation, emphasized Russia's greatest interest in the technology transfer and localization of full-cycle production for biotech drugs, treatments for rare diseases, and drugs not yet registered in the country. These priorities are closely aligned with Nanolek's strategic development goals.
Nanolek is actively expanding its collaboration with biotechnology companies in China. During a recent working visit, Nanolek representatives successfully conducted negotiations with twelve Chinese pharmaceutical companies and visited two production facilities that manufacture innovative vaccines. These discussions are expected to soon lead to several partnership agreements.
Nanolek has established itself as a reliable and trustworthy partner in the Chinese pharmaceutical market. It is worth mentioning that this year Nanolek, through its cooperation with the international oncology company BeiGene, will resume the supplies of Brukinsa, an anticancer medicine, to Russia.